New Technology Quantitatively Analyzes Alzheimer's Biomarkers Using MR and PET Images
|
By MedImaging International staff writers Posted on 21 Jul 2023 |
|
A novel treatment for Alzheimer's disease utilizes an anti-amyloid antibody drug to reduce amyloid beta proteins in the brain. However, a common side effect, ARIA (Amyloid-Related Imaging Abnormalities), often appears in brain scans of patients using the drug. Therefore, careful monitoring and management of ARIA is crucial when prescribing anti-amyloid antibody drugs. Now, new cutting-edge brain imaging solutions for Alzheimer's disease treatment can enable the analysis of ARIA, thereby improving efficacy and outcomes.
Neurophet (Seoul, South Korea), an artificial intelligence (AI) solution company specializing in brain diseases, has developed a new technology to examine ARIA-E (edema) typically detected by T2-FLAIR, an MRI sequence, and ARIA-H (hemorrhages), primarily identified by GRE or SWI. An amyloid-PET scan is necessary to observe cortical amyloid beta deposition. Neurophet’s advanced technology predicts amyloid positivity through MR images before conducting amyloid-PET scans. The use of MR images for predicting amyloid positivity could provide a cost-effective solution for clinical trials and prognosis monitoring of Alzheimer's disease treatment, given that amyloid-PET scans are costly and their use and reimbursement are severely restricted. Moreover, PET scans are not universally accessible due to the limited availability of PET scanners.
At the recent Alzheimer's Association International Conference (AAIC) 2023, Neurophet showcased its cutting-edge brain imaging analysis technology, which can be applied in clinical trials and the prescription of new Alzheimer's disease drugs. The company's Neurophet AQUA software, a brain MRI analysis tool, analyzes brain atrophy observed in neurodegenerative diseases like Alzheimer's. Another product, the Neurophet SCALE PET software, quantitatively assesses Alzheimer's disease biomarkers using MR and PET images. It provides quantitative measurement of cortical amyloid beta deposition, a known causative agent of Alzheimer's disease. Neurophet is investing in research and development of analysis technology for ARIA side effects and aims to bring the products to market along with the launch of new Alzheimer's disease treatments.
"Neurophet's major products and technologies are expected to be very useful in the process of clinical trials, diagnosis, side effect monitoring and prognosis observation of Alzheimer's disease treatment." said CEO Jake Junkil Been of Neurophet. "We are going all out to develop solutions related to Alzheimer's disease treatment to preemptively target the high-growth Alzheimer's disease treatment market."
Related Links:
Neurophet
Latest General/Advanced Imaging News
- New AI Method Captures Uncertainty in Medical Images
- CT Coronary Angiography Reduces Need for Invasive Tests to Diagnose Coronary Artery Disease
- Novel Blood Test Could Reduce Need for PET Imaging of Patients with Alzheimer’s
- CT-Based Deep Learning Algorithm Accurately Differentiates Benign From Malignant Vertebral Fractures
- Minimally Invasive Procedure Could Help Patients Avoid Thyroid Surgery
- Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery
- AR Application Turns Medical Scans Into Holograms for Assistance in Surgical Planning
- Imaging Technology Provides Ground-Breaking New Approach for Diagnosing and Treating Bowel Cancer
- CT Coronary Calcium Scoring Predicts Heart Attacks and Strokes
- AI Model Detects 90% of Lymphatic Cancer Cases from PET and CT Images
- Breakthrough Technology Revolutionizes Breast Imaging
- State-Of-The-Art System Enhances Accuracy of Image-Guided Diagnostic and Interventional Procedures
- Catheter-Based Device with New Cardiovascular Imaging Approach Offers Unprecedented View of Dangerous Plaques
- AI Model Draws Maps to Accurately Identify Tumors and Diseases in Medical Images
- AI-Enabled CT System Provides More Accurate and Reliable Imaging Results
- Routine Chest CT Exams Can Identify Patients at Risk for Cardiovascular Disease
Channels
Radiography
view channel
Novel Breast Imaging System Proves As Effective As Mammography
Breast cancer remains the most frequently diagnosed cancer among women. It is projected that one in eight women will be diagnosed with breast cancer during her lifetime, and one in 42 women who turn 50... Read more
AI Assistance Improves Breast-Cancer Screening by Reducing False Positives
Radiologists typically detect one case of cancer for every 200 mammograms reviewed. However, these evaluations often result in false positives, leading to unnecessary patient recalls for additional testing,... Read more
Ultrasound
view channel
Deep Learning Advances Super-Resolution Ultrasound Imaging
Ultrasound localization microscopy (ULM) is an advanced imaging technique that offers high-resolution visualization of microvascular structures. It employs microbubbles, FDA-approved contrast agents, injected... Read more
Novel Ultrasound-Launched Targeted Nanoparticle Eliminates Biofilm and Bacterial Infection
Biofilms, formed by bacteria aggregating into dense communities for protection against harsh environmental conditions, are a significant contributor to various infectious diseases. Biofilms frequently... Read more
Nuclear Medicine
view channel
New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more
New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
Ovarian cancer is the most lethal gynecological cancer, with less than a 30% five-year survival rate for those diagnosed in late stages. Despite surgery and platinum-based chemotherapy being the standard... Read more
AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more
General/Advanced Imaging
view channel
New AI Method Captures Uncertainty in Medical Images
In the field of biomedicine, segmentation is the process of annotating pixels from an important structure in medical images, such as organs or cells. Artificial Intelligence (AI) models are utilized to... Read more.jpg "Image: CT coronary angiography for diagnosing coronary artery disease offers advantages over other diagnostic tests (Photo courtesy of 123RF)")
CT Coronary Angiography Reduces Need for Invasive Tests to Diagnose Coronary Artery Disease
Coronary artery disease (CAD), one of the leading causes of death worldwide, involves the narrowing of coronary arteries due to atherosclerosis, resulting in insufficient blood flow to the heart muscle.... Read more
Novel Blood Test Could Reduce Need for PET Imaging of Patients with Alzheimer’s
Alzheimer's disease (AD), a condition marked by cognitive decline and the presence of beta-amyloid (Aβ) plaques and neurofibrillary tangles in the brain, poses diagnostic challenges. Amyloid positron emission... Read more.jpg "Image: Exemplary illustration of the labeling and segmentation process (Photo courtesy of TUM)")
CT-Based Deep Learning Algorithm Accurately Differentiates Benign From Malignant Vertebral Fractures
The rise in the aging population is expected to result in a corresponding increase in the prevalence of vertebral fractures which can cause back pain or neurologic compromise, leading to impaired function... Read moreImaging IT
view channel
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more
Industry News
view channel
Bayer and Google Partner on New AI Product for Radiologists
Medical imaging data comprises around 90% of all healthcare data, and it is a highly complex and rich clinical data modality and serves as a vital tool for diagnosing patients. Each year, billions of medical... Read more
